← signals
2026-07-15·AMD·analyst revision
medup

On July 14, 2026, multiple analysts raised price targets on AMD, including Goldman Sachs, KeyBanc, Bank of America, and...

On July 14, 2026, multiple analysts raised price targets on AMD, including Goldman Sachs, KeyBanc, Bank of America, and TD Cowen, citing improving AI prospects (Source 34, Source 38).

window 30devidence 73confidence score 100price AMD $548.13

confidence score

Strong evidence: 53 independent source classes support this read.

100
medium confidence53 independent source classesofficialnewsothercommunitymarketpasses publish gate
priced-in check

AMD is already up +112% over the recent 30-90 day window.

priced in
as of 2026-07-147d n/a45d n/a90d +112%yahoo

signal brief

On July 14, 2026, multiple analysts raised price targets on AMD, including Goldman Sachs, KeyBanc, Bank of America, and TD Cowen, citing improving AI prospects (Source 34, Source 38). Concurrently, AMD announced its Zen 6 Epyc server chip with 256 cores and 1.7x AI performance uplift, targeting data center AI workloads (Source 45). Additionally, Silo Pharma joined the AMD AI Developer Program, expanding the ecosystem (Source 57). These developments signal growing confidence in AMD's AI roadmap despite broader chip market weakness due to geopolitical tensions (Source 15, Source 17). However, the State of Michigan Retirement System lowered its position, indicating some institutional caution (Source 61). Overall, positive analyst revisions and product momentum outweigh near-term macro headwinds.

What the sources said:

  • "Goldman Sachs Raises its Price Target on Advanced Micro Devices, Inc. (AMD)" — Source 34
  • "AMD Stock Surges as KeyBanc, Bank of America, and TD Cowen Turn More Bullish" — Source 38
  • "AMD Zen 6 Epyc chip packs 256 cores, promises up to 1.7x faster AI" — Source 45
  • "Silo Pharma QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform" — Source 57

source data used

spillover entities

INTC

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.